Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

Drug development in acute myeloid leukaemia picks up pace

touchHAEMATOLOGY

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

Haematological Malignancies

2 mins

Johan de Munter, EBMT 2023: Highlights from the Nurses Group Keynote Lecture

Published Online: Jun 27th 2023

President of the European Oncology Nursing Society, Johan de Munter, discusses the key take-home messages from his Nurses Group Keynote Lecture at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, 23-26 April 2023.

Questions:

Please summarise the key points from your Nurses Group Keynote Lecture presented at the EBMT conference 2023 (00:18)

Disclosures: Johan de Munter has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of EBMT 2023.

Supporting young haematologists: Insights on YoungEHA and EHA 24

Mandy Lauw

Dr. Mandy Lauw, outgoing Chair of the YoungEHA Committee, discusses how YoungEHA supports young hematology professionals and offers tips on maximizing the EHA Congress for career development. Topics covered include the main aim and mission of YoungEHA, YoungEHA's contributions to this year’s EHA Congress and throughout the year, how young professionals can get the most out of the EHA Congress and its available activities and resources, making the most of virtual attendance, the main aims of the YoungEHA committee for the coming year and Dr. Lauw's hopes for the committee's future.

Related Videos in Haematological Malignancies

Developed by Touch

Promising data in advancing CAR T-cell therapy outcomes

Dr Sridhar Chaganti

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in the treatment of relapsed or refractory haematological cancers, fundamentally altering the landscape of cancer care. By harnessing the body’s immune system, this therapy effectively targets and destroys cancer cells, demonstrating remarkable efficacy particularly in acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma. At the forefront of advancements discussed during EBMT 2024, Dr. Sridhar Chaganti highlighted pioneering strategies, including the development of allogeneic CAR T-cell therapies. These therapies not only exhibit potential in reducing Graft-versus-Host disease but also show promise in improving cell expansion, marking significant progress in overcoming treatment limitations. Moreover, innovative approaches aim to address associated side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Among these, the introduction of the JAK1 inhibitor, itacitinib, stands out as a promising avenue for mitigating adverse reactions and enhancing patient outcomes in the realm of CAR T-cell therapy

Developed by Touch

Emerging treatment strategies in GVHD

Dr Francesca Kinsella

Recent studies have highlighted the promising effects of belumosudil, axatilimab and faecal microbiota transplants in treating Graft-versus-Host Disease (GVHD). These significant advancements were underscored at the EBMT 50th Annual Meeting

Developed by Touch

Mark Levis, EHA 2023: MORPHO trial of gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia

BMT-CTN1506 (“MORPHO”) was an international phase III trial investigating the use of post-haematopoietic cell transplantation maintenance with the FLT3 inhibitor, gilteritinib, in patients with FLT3-ITD acute myeloid leukaemia. The aims and findings of the trial, as well as questions ...

Developed by Touch

Jorge Cortes, EHA 2023: The use of quizarpenib in patients with acute myeloid leukaemia

We caught up with Prof Jorge Cortes (Georgia Cancer Center, Augusta University, GA, USA) to discuss his highlights from the recent EHA 2023 Congress, including two clinical trials that investigated the use of quizarpenib in patients with acute myeloid leukaemia. Abstracts ...

Developed by Touch

John Mascarenhas, EHA 2023: Phase II MANIFEST trial: Pelabresib combined with ruxolitinib for patients with myelofibrosis

The phase II MANIFEST trial (NCT02158858) investigated the use of pelabresib combined with ruxolitinib for patients with myelofibrosis who are JAK inhibitor treatment-naïve. We caught up with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA), ...

Developed by Touch

John Mascarenhas, EHA 2023: Overview and limitations of current therapeutic options for myelofibrosis

Myelofibrosis is a complex haematological malignancy for which the current first-line treatment is Janus kinase inhibitors. touchHAEMATOLOGY caught up with one of our valued Editorial Board members, Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA) to ...

Developed by Touch

Marina Kremyanskaya, EHA 2023: Findings of the REVIVE study of rusfertide in polycythaemia vera

The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. touchHAEMATOLOGY caught up with Dr Marina Kremyanskaya (Icahn School of Medicine at ...

Developed by Touch

Marina Kremyanskaya, EHA 2023: The REVIVE study of rusfertide in polycythaemia vera – aims and methodology

The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. The unmet needs in the treatment of polycythaemia vera and the aims, ...

Developed by Touch

Anna Sureda, EBMT23: Updates on the GoCART coalition

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares updates from the joint EBMT-EHA session on GoCART. This is a multi-stakeholder coalition of patient representatives, health care professionals, pharmaceutical companies, regulators, Health Technology Assessment ...

Developed by Touch

Anna Sureda, EBMT23: The lastest from the HARMONY Alliance and the Big Data Platform

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares updates from the HARMONY Alliance, a partnership of more than 100 European organizations such as hospitals, research institutes, patient organizations, pharmaceutical companies, regulatory agencies, IT companies ...

Developed by Touch

Robin Foa, EBMT23: Should we transplant all patients with Philadelphia positive ALL?

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (allo-HCT) is the current recommended treatment. Professor Robin Foà (Sapienza University of Rome, Italy) joins us after the EBMT23 meeting to discuss ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Drug development in acute myeloid leukaemia picks up pace

Conference Coverage

Learning Activities

Journals

Drug development in acute myeloid leukaemia picks up pace

Johan de Munter, EBMT 2023: Highlights from the Nurses Group Keynote Lecture

Supporting young haematologists: Insights on YoungEHA and EHA 24

Promising data in advancing CAR T-cell therapy outcomes

Emerging treatment strategies in GVHD

Mark Levis, EHA 2023: MORPHO trial of gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia

Jorge Cortes, EHA 2023: The use of quizarpenib in patients with acute myeloid leukaemia

John Mascarenhas, EHA 2023: Phase II MANIFEST trial: Pelabresib combined with ruxolitinib for patients with myelofibrosis

John Mascarenhas, EHA 2023: Overview and limitations of current therapeutic options for myelofibrosis

Marina Kremyanskaya, EHA 2023: Findings of the REVIVE study of rusfertide in polycythaemia vera

Marina Kremyanskaya, EHA 2023: The REVIVE study of rusfertide in polycythaemia vera – aims and methodology

Anna Sureda, EBMT23: Updates on the GoCART coalition

Anna Sureda, EBMT23: The lastest from the HARMONY Alliance and the Big Data Platform

Robin Foa, EBMT23: Should we transplant all patients with Philadelphia positive ALL?

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

Johan de Munter, EBMT 2023: Highlights from the Nurses Group Keynote Lecture

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Functionality is for
Members Only